Loading
NASDAQHealthcareBiotechnology
Latest quote
$3.71
+$0.10 · +2.77%
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
Previous close
$3.71
+$0.10 · +2.77%
Regular session · ET · Market data may be delayed.
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
Day range
Current $3.71
52-week range
Current $3.71
Regular session · ET · Market data may be delayed.
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
Day range
Current $3.71
52-week range
Current $3.71
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 47.48M USD | 301.83M USD | 16.69M USD | 6.88M USD | 4.34M USD |
| Cost of goods sold | 3.26M USD | 13.75M USD | 1.26M USD | 881.75K USD | 1.47M USD |
| Gross profit | 44.22M USD | 288.08M USD | 15.42M USD | 5.99M USD | 2.87M USD |
| Research and development | 7.09M USD | 1.91M USD | 342K USD | 224.78K USD | 119.65K USD |
| Selling, general, and administrative | 37.82M USD | 254.75M USD | 22.63M USD | 10.21M USD | 4.19M USD |
| Operating expenses | 44.91M USD | 256.88M USD | 23.2M USD | 10.67M USD | 4.47M USD |
| Interest income | 413.85K USD | — | — | — | — |
| Interest expense | — | 587.22K USD | 700.33K USD | 468.15K USD | 525.88K USD |
| Depreciation and amortization | 219.42K USD | 293.22K USD | 229.02K USD | 243.42K USD | 283.9K USD |
| Operating income | −689.15K USD | 31.2M USD | −7.78M USD | −4.68M USD | −1.61M USD |
| Net income | −6.58M USD | 31.88M USD | −8.48M USD | −7.19M USD | −1.45M USD |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$7.00
88.68% upsideAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
